Real-world data on safety and efficacy of venetoclax-based regimens in relapsed/refractory t(11;14) multiple myeloma.
Adult
Bridged Bicyclo Compounds, Heterocyclic
/ administration & dosage
Chromosomes, Human, Pair 11
/ genetics
Chromosomes, Human, Pair 14
/ genetics
Erythrocyte Transfusion
Female
Humans
Male
Multiple Myeloma
/ diagnosis
Platelet Transfusion
Proto-Oncogene Proteins c-bcl-2
/ antagonists & inhibitors
Sulfonamides
/ administration & dosage
Translocation, Genetic
amyloid
amyloidosis
relapsed/refractory multiple myeloma
translocation
venetoclax
Journal
British journal of haematology
ISSN: 1365-2141
Titre abrégé: Br J Haematol
Pays: England
ID NLM: 0372544
Informations de publication
Date de publication:
06 2020
06 2020
Historique:
received:
04
11
2019
accepted:
04
12
2019
pubmed:
6
2
2020
medline:
26
1
2021
entrez:
4
2
2020
Statut:
ppublish
Résumé
The treatment for relapsed/refractory multiple myeloma (RRMM) continues to be challenging despite recent therapeutic advancements. Venetoclax, an inhibitor of the anti-apoptotic protein BCL-2, is a promising agent, especially in patients harbouring t(11;14). Our objective was to review our experience with venetoclax-based regimens at our institution. All ten RRMM patients treated with venetoclax were included and had a median of six prior lines of therapy. The overall response rate was 78% and one patient with cardiac amyloidosis and MM achieved a cardiac organ response. Haematologic toxicities requiring red blood cell and platelet transfusion and non-haematologic toxicities, most commonly gastrointestinal upset, were observed.
Identifiants
pubmed: 32012228
doi: 10.1111/bjh.16454
pmc: PMC9291136
doi:
Substances chimiques
BCL2 protein, human
0
Bridged Bicyclo Compounds, Heterocyclic
0
Proto-Oncogene Proteins c-bcl-2
0
Sulfonamides
0
venetoclax
N54AIC43PW
Types de publication
Clinical Trial
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
1136-1140Commentaires et corrections
Type : CommentIn
Informations de copyright
© 2020 The Authors. British Journal of Haematology published by British Society for Haematology and John Wiley & Sons Ltd.
Références
Am J Hematol. 2019 Jan;94(1):E35-E37
pubmed: 30370955
Blood. 2017 Nov 30;130(22):2401-2409
pubmed: 29018077
Blood Adv. 2021 Oct 12;5(19):3748-3759
pubmed: 34470049
Exp Hematol. 2018 May;61:10-25
pubmed: 29477371
Leukemia. 2018 Feb;32(2):252-262
pubmed: 29257139
Mol Cancer Ther. 2016 May;15(5):1132-44
pubmed: 26939706
Lancet Oncol. 2016 Aug;17(8):e328-e346
pubmed: 27511158
Leukemia. 2017 Nov;31(11):2443-2448
pubmed: 28620163
Leukemia. 2018 Sep;32(9):1899-1907
pubmed: 30076373
Am J Hematol. 2020 Feb;95(2):E34-E35
pubmed: 31709578
Blood. 2017 Nov 30;130(22):2392-2400
pubmed: 28847998